Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Victoria Mateos

Showing results (141-150 of 231) with videos related to

Pageof 24
Sort By:
Haematologica|March 31, 2022
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Wojciech Legiec, et al.
Blood Cancer Journal|March 7, 2023
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUSPhilippe Moreau, Ajai Chari, Albert Oriol, et al.
Bone Marrow Transplantation|August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMTRémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
BMC Cancer|June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialStefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
Blood|January 25, 2012
IMWG consensus on maintenance therapy in multiple myelomaHeinz Ludwig, Brian G M Durie, Philip McCarthy, et al.
British Journal of Haematology|May 4, 2017
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myelomaJacob P Laubach, Javid J Moslehi, Sanjeev A Francis, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
The New England Journal of Medicine|June 3, 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaSagar Lonial, Meletios Dimopoulos, Antonio Palumbo, et al.
Advances in Therapy|February 24, 2024
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple MyelomaHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Blood Cancer Journal|October 31, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaAlejandro Medina, Noemi Puig, Juan Flores-Montero, et al.
Pageof 24

Showing results (141-150 of 231) with videos related to

Sort By:
Pageof 24
Haematologica|March 31, 2022
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Wojciech Legiec, et al.
Blood Cancer Journal|March 7, 2023
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUSPhilippe Moreau, Ajai Chari, Albert Oriol, et al.
Bone Marrow Transplantation|August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMTRémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
BMC Cancer|June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialStefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
Blood|January 25, 2012
IMWG consensus on maintenance therapy in multiple myelomaHeinz Ludwig, Brian G M Durie, Philip McCarthy, et al.
British Journal of Haematology|May 4, 2017
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myelomaJacob P Laubach, Javid J Moslehi, Sanjeev A Francis, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
The New England Journal of Medicine|June 3, 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaSagar Lonial, Meletios Dimopoulos, Antonio Palumbo, et al.
Advances in Therapy|February 24, 2024
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple MyelomaHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Blood Cancer Journal|October 31, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaAlejandro Medina, Noemi Puig, Juan Flores-Montero, et al.
Pageof 24